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The concept of a scar carcinoma was first introduced almost 80 
years  ago.[1] The presence of dense hyaline scarring in the centre of 
many primary peripheral lung carcinomas led to recognition of the 
phenomenon of a lung scar carcinoma, although it was not clear 
whether the relevant area of scarring preceded the carcinoma or was 
caused by the carcinoma.[1,2]
In recent years there has been renewed interest in scar carcinomas, 
also referred to as ‘scar-cinomas’.[2] It has been reported that the 
presence of large numbers of fibroblasts and myofibroblasts is a 
hallmark of carcinomas.[3] Moreover, malignant cells hijack the host 
wound-repair response to promote formation of the tumour stroma, 
which is fundamental for cancer progression.[3] The persistence of 
activated mesenchymal cells is therefore critical to the pathobiology 
of both fibrosis and cancer.[2,3]
The Western Cape Province of South Africa (SA) has one of the 
highest recorded incidences of pulmonary tuberculosis (TB) in the 
world, and also carries a high burden of smoking-related diseases 
including lung cancer.[4] However, the potential association between 
pulmonary scarring and lung cancer has never been described in the 
local population.
Objective
The main objective of this study was to assess the frequency of 
pulmonary scarring in all patients with lung cancer, and whether or 
not scarring was likely to be present in the same lobe as the lung cancer.
Methods
We retrospectively identified all patients with primary lung cancer 
who had presented to Tygerberg Academic Hospital and had their 
information captured on a prospective registry updated weekly 
during the combined multidisciplinary chest oncology meeting from 
January 2012 to December 2013. Tygerberg Hospital is a 1 380-bed 
tertiary facility in Cape Town, SA. It is one of two referral centres in the 
city and renders a tertiary service to a population of about 1.5 million 
with a TB incidence of approximately 1 000/100 000 population.[5] We 
collected data on all patients with a known diagnosis of lung cancer and 
who underwent a staging computed tomography (CT) scan. Routine 
demographic and clinical data were collected, including smoking status 
(to qualify as a smoker, a patient had to have smoked at least 10 pack-
years per lifetime) and performance status according to the Eastern 
Cooperative Oncology Group (ECOG).
All patients had access to positron emission tomography-CT, 
bronchoscopy with endobronchial ultrasound-guided transbronchial 
needle aspiration with rapid onsite evaluation, transthoracic image-
guided biopsy (ultrasound or CT) and related diagnostic techniques 
that were performed at the discretion of the treating physicians as 
per standard operating procedures. Patients were subsequently staged 
according to the 2009 International Association for the Study of Lung 
Cancer TNM staging system (7th edition).[6]
Pulmonary scarring (Fig. 1) was assessed by two experienced 
radiologists (blinded to the histological diagnosis) and categorised 
according to location as present in: (i) the same lobe as the primary 
tumour, (ii) a different lobe of the same lung, or (iii) some part of the 
contralateral lung; or (iv) as diffuse. Post-obstructive bronchiectasis 
and other changes secondary to the lung cancer itself were considered 
not to represent scarring.
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Background. The association between lung scarring and the subsequent development of cancer remains controversial. South Africa has one 
of the highest incidences of tuberculosis in the world, and resultant scarring may predispose to malignancy. The country also carries a very 
high burden of smoking and smoking-related diseases that may be synergistic in malignant transformation.
Objective. To assess the frequency of pulmonary scarring in patients with lung cancer.
Methods. All patients with confirmed lung cancer and a staging computed tomography (CT) scan of the chest were included in this 2-year 
retrospective study. Pulmonary scarring was categorised according to location as present in: (i) the same lobe as the primary tumour, (ii) a 
different lobe of the same lung, or (iii) the contralateral lung; or (iv) as diffuse. Post-obstructive bronchiectasis and other changes secondary 
to cancer were considered not to represent scarring.
Results. We identified 435 cases of primary lung cancer. In total, 95 patients (21.8%) had CT evidence of pulmonary scarring. Eighty-three 
of 85 patients (97.6%) had focal scarring in the same lobe as the primary tumour. Of these, 37 (43.5%) also had scarring involving a different 
lobe of the same lung, whereas only one (1.2%; p<0.001) had scarring isolated to a different lobe of the same lung. Moreover, 21 patients 
(24.7%) also had scarring of the opposite lung, but only one patient (1.2%; p<0.001) had scarring isolated to the contralateral lung. Ten 
patients had diffuse scarring, caused by bronchiectasis (n=5), idiopathic pulmonary fibrosis (n=4) and silicosis (n=1).
Conclusion. At least one in five patients with lung cancer had scarring, which was significantly more likely to be present in the same lobe as 
the tumour, suggesting a predisposition to malignancy.
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S13/04/078). The application included a waiver of consent owing to 
the retrospective nature and anonymity of the study design.
Statistical analysis
Descriptive statistics and χ2 comparisons of proportional data were 
performed. A p-value <0.05 in a two-tailed test of proportions (χ2) 
was considered significant.
Results
Of 508 patients with lung cancer identified, 435 had staging CT 
scans (mean age (standard deviation (SD)) 60.1 (10.4) years), 
266 males) (Table 1). Of these, 95 patients (21.8%) had CT evidence 
of pulmonary scarring. Patients with scarring were younger than 
those without scarring (mean 57.9 (10.2) years v. 60.7 (10.4) years; 
p=0.02), with a male predominance in both groups (62/95 (65.3%) 
and 204/340 (60.0%); p=0.35). Cigarette smoking exposure between 
the groups was equal, with regard to both proportion of smokers 
(85/95 (89.5%) v. 308/340 (90.6%); p=0.89) and pack-years (27.9 
v. 31.0; p=0.22). The distribution of non-small-cell lung cancer 
(NSCLC) (n=375) and small-cell lung cancer (SCLC) (n=60) was 
comparable between the groups, as was tumour staging (Table 1).
Eighty-three of 85 patients (97.6%) had focal scarring in the same 
lobe as the primary tumour. Of these, 37 (43.5%) also had scarring 
involving a different lobe of the same lung, whereas only one (1.2%; 
p<0.001) had scarring isolated to a different lobe of the same lung. 
Moreover, 21 patients (24.7%) also had scarring of the opposite 
lung, but only one patient (1.2%; p<0.001) had scarring isolated 
to the contralateral lung. Ten patients had diffuse scarring; causes 
included bronchiectasis (n=5), idiopathic pulmonary fibrosis (n=4) 
and silicosis (n=1).
Discussion
We found a very strong association, albeit it not a temporal association, 
between pulmonary scarring and lung cancer. At least one in five 
patients who presented with lung cancer had radiological evidence of 
associated scarring. Moreover, scarring was significantly more likely 
to be present in the same lobe as the tumour than in a different lobe, 
suggesting an association between scarring and lung cancer. Patients 
with pulmonary scarring and lung cancer were significantly younger 
than those without scarring, but gender, histological features, staging 
and smoking history were comparable between the two groups of 
patients.
Our study largely echoed findings of previous studies with regard 
to the existence of a strong anatomical relationship between a 
pulmonary malignancy and an associated area of fibrosis, as well as a 
predominance of adenocarcinomas in these malignancies. However, 
Fig. 1. An adenocarcinoma (arrow) in the background of structural lung 
disease (previous pulmonary TB).
Table 1. Demographics, lung cancer type, staging and performance status of all patients (N=435)
Scarring present (N=95) Scarring absent (N=340) p-value
Age (yr), mean (SD) 57.9 (10.2) 60.7 (10.4) 0.02
Sex, n (%)
Males 62 (65.2) 204 (60.0) 0.35
Smoking status
Smokers, n (%) 85 (89.5) 308 (90.6) 0.89
Pack-years, mean (SD) 27.9 (16.0) 31.0 (19.3) 0.22
Lung cancer type, n (%) 0.76
Adenocarcinoma 41 (43.2) 137 (40.3)
Squamous cell 26 (27.4) 77 (22.6)
Poorly differentiated 13 (13.7) 67 (19.7)
SCLC 14 (14.7) 46 (13.5)
Other 1 (1.1) 12 (4.7)
NSCLC staging (N=375)*, n (%) 0.89
I 3 (3.7) 9 (3.4)
II 4 (4.9) 14 (5.3)
IIIA 3 (3.7) 19 (7.2)
IIIB 13 (16.0) 65 (24.6)
IV 58 (71.6) 187 (70.8)
SCLC staging (N=60), n (%) 1.00 
Limited 3 (21.4) 10 (27.8)
Extensive 11(78.6) 36 (78.2)
ECOG performance status, n (%) 0.49
1 - 2 61 (64.2) 231 (67.9)
3 - 4 34 (36.8) 109 (32.1)
*Of the 375 patients, 81 had scarring and 264 had no scarring.
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we found a larger proportion of scar carcinomas in comparison 
with previous studies. Auerbach et al.[7] reported autopsy findings 
on 1 186  cases of primary lung cancer and showed that 82 cases 
(6.9%) had an associated focus of pulmonary fibrosis. Raeburn and 
Spencer,[1] who performed an autopsy study on 400 cases of lung 
cancer, found that 15 (3.8%) of the cancers fitted the definition 
of a scar carcinoma. Freant et al.[8] observed a 20% prevalence of 
pulmonary scar carcinomas in 94 surgically excised primary lung 
cancers. The higher proportion in our population is probably 
related to the high prevalence of post-tuberculous lung disease in 
the Western Cape. Patients with a history of pulmonary TB have 
been shown to display a two-fold increase in risk for the subsequent 
development of lung cancer.[9]
The pathogenesis of lung fibrosis is accepted to be due to 
the accumulation of activated reparative mesenchymal cells (myo-
fibroblasts) and their persistent unopposed deposition of extracellular 
matrix (ECM).[10] It is hypothesised that this unopposed accumulation 
of ECM interacts malignantly with surrounding epithelial cells 
by disturbing their normal cell cycles and promoting subsequent 
mutations.[11]
Studies evaluating fibrotic biopsies from patients with idiopathic 
pulmonary fibrosis (IPF) have shown a paucity of apoptosis, similar 
to that of malignancies, which may indicate a synonymous ability 
of both fibrotic and malignant tissue to evade cell death.[2,10] A 
possible explanation for this lack of apoptosis could be explained by 
overexpression of anti-apoptotic protein kinases, such as survivin.[12] 
Furthermore, the process of autophagy, by which cell death occurs via 
the lysosomal pathway, has been shown to be impaired in IPF as well 
as fibroblast models. Impaired autophagy is a commonly accepted 
mechanism of tumourigenesis.[2]
Sustained proliferative signalling is also considered to be a hallmark 
of tumourigenesis, in which sustained exogenous stimuli ‘hijack’ the 
cell cycle.[13] This overexpression of proliferative signalling networks 
has been shown also to be present in fibroblasts from IPF biopsies. 
Another accepted hallmark of malignant tissue is its ability to evade 
growth suppressors. Prostaglandin E2 (PGE2) is a cell mediator that 
inhibits proliferation, differentiation and collagen synthesis of normal 
fibroblasts as well as promoting their susceptibility to apoptosis. 
However, fibroblasts within IPF, similarly to malignant cells, have been 
shown to demonstrate less sensitivity to the effects of PGE2.[2,13]
Our study has implications for both routine clinical care and future 
research. Although not specifically designed to test the hypothesis, 
our findings suggest that scarring (from any cause) should be viewed 
as a risk factor for lung cancer, and that extra vigilance is required 
when following up patients with existing scarring, particularly if they 
are smokers or have any clinical or radiological features of cancer. 
Prospective studies are needed to gauge the true risk associated with 
pulmonary scarring, particularly secondary to TB.
Study limitations
Our study has some limitations, most notably its retrospective 
nature and the lack of histological confirmation of apparent scarring 
observed on CT scanning. Moreover, our registry was not set up to 
capture HIV status or a history of previous pulmonary TB. However, 
in the vast majority of cases with focal scarring, the CT scan was 
consistent with changes of previous TB.
Conclusion
At least 20% of patients with lung cancer had scarring, which was 
significantly more likely to be present in the same lobe as the lung 
cancer than elsewhere in the lungs, suggesting a predisposition to 
malignancy.
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